Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03221426 |
Title | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Merck Sharp & Dohme Corp. |
Indications | |
Therapies |
Capecitabine + Cisplatin + Pembrolizumab |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | FRA | DEU | CAN | BEL |